Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Fontus Health Ltd, 60 Lichfield Street, Walsall WS4 2BX, United Kingdom
Hanixol 50 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablets. Round 7.4 mm yellowish tablet, scored. |
Each Tablet contains 50 mg of 6-mercaptopurine.
Excipients with known effect:
Lactose anhydrous: 59 mg per tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Mercaptopurine |
Mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity. The mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. The thioguanine nucleotides are also incorporated into nucleic acids and this contributes to the cytotoxic effects of the active substance. |
| List of Excipients |
|---|
|
Lactose anhydrous |
Type III 20 ml amber glass bottle containing 25 tablets with a polypropylene child-proof cap and silica gel desiccant.
Fontus Health Ltd, 60 Lichfield Street, Walsall WS4 2BX, United Kingdom
PL 42924/0019
07/03/2019
| Drug | Countries | |
|---|---|---|
| HANIXOL | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
